All Stories

  1. AhR and IDO1 in pathogenesis of Covid-19 and the “Systemic AhR Activation Syndrome:” a translational review and therapeutic perspectives
  2. The Influence of Palmatine Isolated from Berberis sibirica Radix on Pentylenetetrazole-Induced Seizures in Zebrafish
  3. Phenotypic Characterization of Larval Zebrafish (Danio rerio) with Partial Knockdown of the cacna1a Gene
  4. Kynurenic acid and cancer: facts and controversies
  5. Changes in tryptophan and kynurenine pathway metabolites in the blood of children treated with ketogenic diet for refractory epilepsy
  6. Quinaldic acid induces changes in the expression of p53 tumor suppressor both on protein and gene level in colon cancer LS180 cells
  7. The presence and distribution of G protein-coupled receptor 35 (GPR35) in the human cornea – Evidences from in silico gene expression analysis and immunodetection
  8. Fate and distribution of kynurenic acid administered as beverage
  9. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro
  10. Kynurenic Acid Protects against Thioacetamide-Induced Liver Injury in Rats
  11. Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro
  12. Tryptophan, kynurenine, kynurenic acid concentrations and indoleamine 2,3-dioxygenase activity in serum and milk of dairy cows with subclinical mastitis caused by coagulase-negative staphylococci
  13. Effect of Kynurenic Acid on Pupae Viability of Drosophila melanogaster cinnabar and cardinal Eye Color Mutants with Altered Tryptophan-Kynurenine Metabolism
  14. Quinaldic acid in synovial fluid of patients with rheumatoid arthritis and osteoarthritis and its effect on synoviocytes in vitro
  15. Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye
  16. Effects of tryptophan, kynurenine and kynurenic acid exerted on human reconstructed corneal epithelium in vitro
  17. Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain—Its Possible Clinical Applications
  18. The effect of three angiotensin-converting enzyme inhibitors on kynurenic acid production in rat kidney in vitro
  19. Influence of picolinic acid on seizure susceptibility in mice
  20. Angiotensin-converting enzyme inhibitors modulate kynurenic acid production in rat brain cortex in vitro
  21. Kynurenic Acid Induces Impairment of Oligodendrocyte Viability: On the Role of Glutamatergic Mechanisms
  22. Protective action of nicotinic acid benzylamide in a variety of chemically-induced seizures in mice
  23. The effect of kynurenic acid on the synthesis of selected cytokines by murine splenocytes – in vitro and ex vivo studies
  24. Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord
  25. Cholinesterase activity in blood and pesticide presence in sweat as biomarkers of children`s environmental exposure to crop protection chemicals
  26. Trace metal analyses in honey samples from selected countries. A potential use in bio-monitoring
  27. Quinaldic acid inhibits proliferation of colon cancer HT-29 cells in vitro: Effects on signaling pathways
  28. Serum tryptophan and its metabolites in female dogs undergoing ovariohysterectomy as treatment of pyometra or as elective spay surgery
  29. Kynurenic Acid Content in Selected Culinary Herbs and Spices
  30. On the toxicity of kynurenic acid in vivo and in vitro
  31. Effects of systemic administration of kynurenic acid and glycine on renal haemodynamics and excretion in normotensive and spontaneously hypertensive rats
  32. Kynurenic acid inhibits colon cancer proliferation in vitro: effects on signaling pathways
  33. Modulation by kynurenine of extracellular kynurenate and glutamate in cerebral cortex of rats with acute liver failure
  34. Orphenadrine-induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine
  35. Kynurenic acid inhibits proliferation and migration of human glioblastoma T98G cells
  36. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice
  37. Presence and distribution of l-kynurenine aminotransferases immunoreactivity in human cataractous lenses
  38. Effect of dietary administration of kynurenic acid on the activity of splenocytes of the rainbow trout (Oncorhynchus mykiss)
  39. Tryptophan-Kynurenine Metabolism and Insulin Resistance in Hepatitis C Patients
  40. Kynurenic acid – a new tool in the treatment of hiperhomocysteinemia and its consequences?
  41. Potato- An Important Source of Nutritional Kynurenic Acid
  42. Kynurenic acid in human renal cell carcinoma: its antiproliferative and antimigrative action on Caki-2 cells
  43. Main dietary compounds and pancreatic cancer risk. The quantitative analysis of case–control and cohort studies
  44. Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats
  45. Kynurenic acid synthesis and kynurenine aminotransferases expression in colon derived normal and cancer cells
  46. Orphenadrine induces secondarily generalized convulsive status epilepticus in rats
  47. Distribution, Synthesis, and Absorption of Kynurenic Acid in Plants
  48. Neuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat—possible involvement of kynurenic acid
  49. Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats
  50. Kynurenic acid in blood and bone marrow plasma of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) patients
  51. Long-term exposure to nicotine markedly reduces kynurenic acid in rat brain — In vitro and ex vivo evidence
  52. High concentration of kynurenic acid in bile and pancreatic juice
  53. Sedative and anticonvulsant drugs suppress postnatal neurogenesis
  54. Anticonvulsant and acute adverse effect profiles of picolinic acid 2-fluoro-benzylamide in various experimental seizure models and chimney test in mice
  55. Micromolar concentration of kynurenic acid in rat small intestine
  56. Presence of kynurenic acid in food and honeybee products
  57. Characterization of the anticonvulsant profile of isonicotinic acid benzylamide in various experimental seizure models in mice
  58. Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing-remitting multiple sclerosis
  59. NMDA antagonists exert distinct effects in experimental organophosphate or carbamate poisoning in mice
  60. Lithium–methomyl induced seizures in rats: A new model of status epilepticus?
  61. Elevated Concentrations of Kynurenic Acid, a Tryptophan Derivative, in Dense Nuclear Cataracts
  62. Ammonia at pathophysiologically relevant concentrations activates kynurenic acid synthesis in cultured astrocytes and neurons
  63. Enhancement of brain kynurenic acid production by anticonvulsants—Novel mechanism of antiepileptic activity?
  64. Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro
  65. Kynurenic acid synthesis in bovine retinal slices – effect of glutamate agonists
  66. Kynurenic acid, an endogenous constituent of rheumatoid arthritis synovial fluid, inhibits proliferation of synoviocytes in vitro
  67. Demonstration of Kynurenine Aminotransferases I and II and Characterization of Kynurenic Acid Synthesis in Oligodendrocyte Cell Line (OLN-93)
  68. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons
  69. Dual effect ofDL-homocysteine andS-adenosylhomocysteine on brain synthesis of the glutamate receptor antagonist, kynurenic acid
  70. Ethosuximide and valproate display high efficacy against lindane-induced seizures in mice
  71. Carbamazepine enhances brain production of kynurenic acid in vitro
  72. Age-dependent decrease of retinal kynurenate and kynurenine aminotransferases in DBA/2J mice, a model of ocular hypertension
  73. Kynurenic acid in ALS patients
  74. Kynurenic acid production in cultured bovine aortic endothelial cells. Homocysteine is a potent inhibitor
  75. Kynurenic acid synthesis in cerebral cortical slices of rats with progressing symptoms of thioacetamide-induced hepatic encephalopathy
  76. Content of Kynurenic Acid and Activity of Kynurenine Aminotransferases in Mammalian Eyes
  77. Expression of kynurenine aminotransferases in the rat retina during development
  78. l-Cysteine sulphinate, endogenous sulphur-containing amino acid, inhibits rat brain kynurenic acid production via selective interference with kynurenine aminotransferase II
  79. Ontogenic changes of kynurenine aminotransferase I activity and its expression in the chicken retina
  80. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis
  81. Dizocilpine Improves Beneficial Effects of Cholinergic Antagonists in Anticholinesterase-Treated Mice
  82. Alterations of kynurenic acid content in the retina in response to retinal ganglion cell damage
  83. Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients
  84. 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats
  85. Regulation of kynurenic acid synthesis in C6 glioma cells
  86. AMPA and GABAB receptor antagonists and their interaction in rats with a genetic form of absence epilepsy
  87. Amlodipine enhances the activity of antiepileptic drugs against pentylenetetrazole-induced seizures
  88. Kynurenine Aminotransferase I Activity in Human Placenta
  89. On the interactions between antimuscarinic atropine and NMDA receptor antagonists in anticholinesterase-treated mice
  90. Amino Acid Derivatives with Anticonvulsant Activity.
  91. Evidence for Intraocular Synthesis of Kynurenic Acid, a Putative Endogenous Neuroprotectant
  92. Formation of endogenous glutamatergic receptors antagonist kynurenic acid — differences between cortical and spinal cord slices
  93. Proconvulsive effects of the mitochondrial respiratory chain inhibitor — 3-nitropropionic acid
  94. NMDA- But Not Kainate-Mediated Events Reduce Efficacy of Some Antiepileptic Drugs Against Generalized Tonic-Clonic Seizures in Mice
  95. AMPA/kainate-related mechanisms contribute to convulsant and proconvulsant effects of 3-nitropropionic acid
  96. Mitochondrial toxin 3-nitropropionic acid evokes seizures in mice
  97. A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice
  98. Felbamate demonstrates low propensity for interaction with methylxanthines and Ca2+ channel modulators against experimental seizures in mice
  99. EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ON THE ANTICONVULSIVE ACTIVITY OF VALPROATE AND DIPHENYLHYDANTOIN AGAINST MAXIMAL ELECTROSHOCK-INDUCED SEIZURES IN MICE
  100. Acute ammonia treatment in vitro and in vivo inhibits the synthesis of a neuroprotectant kynurenic acid in rat cerebral cortical slices
  101. Chlormethiazole anticonvulsive efficacy diminished by N-methyl-d-aspartate but not kainate in mice
  102. Interaction of Calcium Channel Blockers and Excitatory Amino Acid Antagonists with Conventional Antiepileptic Drugs
  103. Interactions of excitatory amino acid antagonists with conventional antiepileptic drugs
  104. Influence of combined treatment with NMDA and non-NMDA receptor antagonists on electroconvulsions in mice
  105. Influence of a Ca2+ channel agonist, BAY k-8644, on the anticonvulsant activity of NMDA and non-NMDA receptor antagonists
  106. The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice
  107. The NMDA antagonist procyclidine, but not ifenprodil, enhances the protective efficacy of common antiepileptics against maximal electroshock-induced seizures in mice
  108. Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology
  109. Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics
  110. 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice
  111. Competitive antagonist of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice
  112. Antiparkinsonian drugs memantine and trihexyphenidyl potentiate the anticonvulsant activity of valproate against maximal electroshock-induced seizures
  113. Age-related changes in kynurenic acid production in rat brain
  114. Age dependency of the susceptibility of rats to aminooxyacetic acid seizures
  115. NBQX does not affect learning and memory tasks in mice: a comparison with D-CPPene and ifenprodil
  116. Kynurenic Acid: A Potential Pathogen in Brain Disorders
  117. Long-Term Effects of Pilocarpine in Rats: Structural Damage of the Brain Triggers Kindling and Spontaneous I Recurrent Seizures
  118. Aminooxyacetic acid produces excitotoxic lesions in the rat striatum
  119. Influence of MK-801 on the anticonvulsant activity of antiepileptics
  120. Systemic kainic acid administration in rats: Effects on kynurenic acid production in vitro and in vivo
  121. Seizures induced by aminooxyacetic acid in mice: Pharmacolgical characteristics
  122. Paradoxical anticonvulsant acitivity of the ?hyphen;Aminobutyrate antagonist bicuculline methiodide in the rat striatum
  123. Excitatory amino acid antagonists and memory: Effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks
  124. Substantia nigra: A site of action of muscle relaxant drugs
  125. Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: Effect of aminooxyacetic acid
  126. Excitatory amino acid antagonists protect mice against seizures induced by bicuculline
  127. Blockade of excitatory neurotransmission in the globus pallidus induces rigidity and akinesia in the rat: implications for excitatory neurotransmission in pathogenesis of Parkinson's diseases
  128. The entopeduncular nucleus regulates muscle tone in genetically spastic rats: role of substance P and γ-aminobutyric acid
  129. Dopamine control of seizure propagation: Intranigral dopamine D1 agonist SKF-38393 enhances susceptibility of seizures
  130. Rat Brain Slices Produce and Liberate Kynurenic Acid upon Exposure to l-Kynurenine
  131. Homocysteic acid: convulsant action of stereoisomers in mice
  132. Review: Cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: A novel experimental model of intractable epilepsy
  133. Differential effects of non-steroidal anti-inflammatory drugs on seizures produced by pilocarpine in rats
  134. Identification and quantification of kynurenic acid in human brain tissue
  135. On the disposition of intrahippocampally injected kynurenic acid in the rat
  136. The susceptibility of rats to pilocarpine-induced seizures is age-dependent
  137. Substantia nigra and motor control in the rat: effect of intranigral α-kainate and γ-d-glutamylaminomethylsulphonate on motility
  138. Effect of Aminophylline and Enprofylline on the Protective Efficacy of Common Antiepileptic Drugs Against Electroconvulsions in Mice
  139. Only certain antiepileptic drugs prevent seizures induced by pilocarpine
  140. Effects ofl-cysteine-sulphinate andl-aspartate, mixed excitatory amino acid agonists, on the membrane potential of cat caudate neurons
  141. Evidence that antagonism at non-NMDA receptors results in anticonvulsant action
  142. Convulsant action of morphine, [d-ala2, d-leu5]-enkephalin and naloxone in the rat amygdala: Electroencephalographic, morphological and behavioural sequelae
  143. Seizures produced by pilocarpine: Neuropathological sequelae and activity of glutamate decarboxylase in the rat forebrain
  144. Effect of Aminophylline on the Protective Action of Common Antiepileptic Drugs Against Electroconvulsions in Mice
  145. Excitatory neurotransmission within substantia nigra pars reticulata regulates threshold for seizures produced by pilocarpine in rats: Effects of intranigral 2-amino-7-phosphonoheptanoate and n-methyl-d-aspartate
  146. Susceptibility to seizures produced by pilocarpine in rats after microinjection of isonnazid or γ-vinyl-GABA into the substantia nigra
  147. Aminophylline and CGS 8216 Reverse the Protective Action of Diazepam Against Electroconvulsions in Mice
  148. Effects of aminophylline and 2-chloroadenosine on seizures produced by pilocarpine in rats: Morphological and electroencephalographic correlates
  149. Modification of the anticonvulsant activity of 2-amino-5-phosphonovalerate by agents affecting different neurotransmitter systems
  150. Phosphonic analogues of excitatory amino acids raise the threshold for maximal electroconvulsions in mice
  151. Muscle relaxant action of 2-chloroadenosine in genetically spastic rats is independent of γ-aminobutyric acid-mediated inhibition
  152. Effects of morphine and naloxone on pilocarpine-induced convulsions in rats
  153. Muscle relaxant action of excitatory amino acid antagonists
  154. Injections of picrotoxin and bicuculline into the amygdaloid complex of the rat: An electroencephalographic, behavioural and morphological analysis
  155. Seizures produced by pilocarpine in mice: A behavioral, electroencephalographic and morphological analysis
  156. Effect of aminophylline on muscle relaxant action of diazepam and phenobarbitone in genetically spastic rats: Further evidence for a purinergic mechanism in the action of diazepam
  157. Effects of excitatory amino-acid antagonists on the anticonvulsant action of phenobarbital or diphenylhydanton in mice
  158. A specific benzodiazepine antagonist CGS 8216 reverses the muscle relaxant effect of diazepam but not that of phenobarbitone
  159. Differential effects of baclofen, ³-hydroxybutyric acid and muscimol on the protective action of phenobarbital and diphenylhydantoin against maximal electroshock-induced seizures in mice
  160. Studies on the Mechanism of Wet Dog Shakes Produced by Carbachol in Rats
  161. Cholinomimetics produce seizures and brain damage in rats
  162. Limbic seizures produced by pilocarpine in rats: Behavioural, electroencephalographic and neuropathological study
  163. Intrahippocampal bethanechol in rats: Behavioural, electroencephalographic and neuropathological correlates
  164. Does morphine withdrawal produce brain damage in rats?
  165. Intraamygdaloid morphine produces seizures and brain damage in rats
  166. Dyphenylhydantoin enhancement of diazepam effects on locomotor activity in mice
  167. Effect of antidepressant drugs on carbachol chloride-induced wet dog shake behaviour in rats
  168. (RS)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid: Wet dog shakes, catalepsy and body temperature changes in rats
  169. Effect of combined treatment of phenytoin with diazepam on the susceptibility of mice to electroconvulsions
  170. Effect of trazodone, mianserin, iprindole and zimelidine on wet dog shakes produced by carbachol in rats
  171. Effects of Some Antiepileptic Drugs in Pentetrazol-Induced Convulsions in Mice Lesioned with Kainic Acid
  172. Evidence against the involvement of serotonergic mechanisms in wet dog shake behavior induced by carbachol chloride in rats
  173. Effects of morphine and nalorphine on kainic acid-induced hypothermia in rats
  174. Studies of carbachol-induced wet-dog shake behavior in rats